A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00241371|
Recruitment Status : Terminated (No response seen in patients)
First Posted : October 18, 2005
Last Update Posted : August 13, 2013
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Clofarabine||Phase 2|
To determine the time to response, duration of response, and time to progression of patients treated with clofarabine.
To determine the safety and tolerability of clofarabine in these patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma|
|Study Start Date :||March 2005|
|Primary Completion Date :||November 2005|
|Study Completion Date :||December 2007|
4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
- Overall response rate (CR+PR) [ Time Frame: Every 3 months ]
- Time to response [ Time Frame: Every 3 months ]
- Safety and tolerability of clofarabine [ Time Frame: 30 days after last treatment ]
- Duration of response [ Time Frame: Every 3 months ]
- Time to progression [ Time Frame: Every 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00241371
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63110|
|Principal Investigator:||Ravi Vij, M.D.||Washington University School of Medicine|